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Abstract
There is currently little systematic knowledge about the contribution of different factors to the increase in health care spending 
in high-income countries such as Switzerland. The aim of this paper is to decompose inpatient care costs in the Swiss canton 
of Zurich by 100 diseases and 42 age/sex groups and to assess the contribution of six factors to the change in aggregate costs 
between 2013 and 2017. These six factors are population size, age and sex structure, inpatient treated prevalence, utilization 
in terms of stays per patient, length of stay per case, and costs per treatment day. Using detailed inpatient cost data at the 
case level, we find that the most important contributor to the change in disease-specific costs was a rise in costs per treatment 
day. For most conditions, this effect was partly offset by a reduction in the average length of stay. Changes in population size 
accounted for one third of the total increase, but population structure had only a small positive association with costs. The 
most expensive cases accounted for the largest part of the increase in costs, but the magnitude of this effect differed across 
diseases. A better understanding of the factors related to cost changes at the disease level over time is essential for the design 
of targeted health policies aiming at an affordable health care system.
Keywords Health care costs · Cost-of-illness · Inpatient care · Switzerland · Cost decomposition
JEL Classification I10 Health general · I11 Analysis of health care markets
Introduction
High and rising health care spending dominates the health 
policy debate in high income countries. OECD countries 
have experienced a strong increase in spending in the last 
few years, raising questions about the sustainability of its 
levels. Switzerland is one of the countries with the highest 
share of health care spending in percent of its GDP in the 
world (12.3% in 2017) [1]. The average annual health care 
spending growth of 3.7% over the last 25 years outpaced 
nominal GDP growth (2.3%). Switzerland also exhibited 
the second largest health care spending per capita after the 
United States with 9,768 Swiss Francs (about 10,000 US 
Dollar) in 2017, which is twice the spending in 1992.
The inpatient care sector accounts for about one-fifth 
of total health care spending in Switzerland [1] and went 
through some reforms recently. As of 2017, there were 281 
hospitals in Switzerland, 102 of which were general hospi-
tals mainly in primary care [2]. In 2013, Switzerland had 
4.7 hospital beds per 1000 people, significantly more than 
the OECD member states average (3.8/1000) [3]. Recent 
changes include the implementation of a DRG (diagnosis-
related groups)-based reimbursement system in 2012, the 
subsequent structural changes in the service provision 
(mainly the shift from inpatient to outpatient treatments) as 
well as the demographic transition which came with chang-
ing morbidity patterns. These issues render the inpatient care 
setting in Switzerland an interesting and relevant case for 
studying the factors associated with the cost increase at the 
level of specific diseases.
This study aims to quantify the contributions of six 
factors related to the change in aggregated inpatient care 
costs in the Canton of Zurich between 2013 and 2017. The 
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decomposition is done by diseases and age/sex groups. We 
define a multiplicative relationship between the six factors 
and apply the rate decomposition method by Das Gupta 
[4] to separate the impact of (1) population growth, (2) age 
and sex structure, (3) the number of treated patients, (4) 
utilization in terms of the number of stays per patient, (5) 
the length of stay and (6) the costs per day by disease on 
the disease-specific cost change. The study shows that the 
increase in costs per day had the strongest effect on the total 
cost increase of about 15%. Since there was at the same time 
a reduction in the length of stay that partly offset this effect, 
our results suggest a compression and increased intensity of 
inpatient treatments.
Our contribution is threefold. First, in contrast to most 
related studies (e.g. [5]), we use cost instead of reimburse-
ment data to decompose cost changes over time. In doing so, 
we focus on the production costs instead of the costs borne 
by payers. This allows us to distinguish between different 
components of total costs such as physician costs, medi-
cal costs and medical products costs, which enables a more 
detailed view of the source of cost changes. In addition, it 
puts more variation into the data compared to if we used the 
case output price resulting from the case weight calculation. 
Even though a DRG system aims at applying a model where 
reimbursement reflects on average production costs, this will 
not work for all diseases and some of the treatment costs 
might not be mirrored in the DRG weight. The use of cost 
data makes sense, as in a dynamic reimbursement system, 
the DRG weights are, to some extent and in the long run, 
a function of the production costs. Second, we include an 
additional factor in the decomposition, namely the length 
of stay by disease. Thereby, we are able to quantify the 
contributions of both length of stay and stays per patient. 
Separating out these factors is important in DRG-based 
reimbursement schemes, in particular after their introduc-
tion. The reason is that decreases in length of stay may be 
offset by increases in stays per patient if, for example, early 
discharges come with a higher rate of hospital readmission. 
Third, we explore cost changes across the full cost distribu-
tion. Uncovering differential impacts of the factors across 
the distribution of case costs by disease may shed light on 
additional effects that are not visible for the average. To the 
best of our knowledge, this is the first study that aims to 
explain the increase in inpatient health care costs with a 
disease-specific costs approach for Switzerland.
This paper is structured as follows. Section 2 gives back-
ground information about the Swiss context and the related 
literature on health care spending drivers. Section 3 intro-
duces the data and section 4 the methodology. The results 
are presented in Sect. 5 for the decomposition at two levels 
of disease classification. Section 6 concludes and discusses 
the main findings as well as the strengths and limitations of 
the study.
Background
The Swiss Health Care System
Switzerland has universal health coverage with a compre-
hensive benefits catalogue. It provides high quality health 
care without waiting times, albeit at high costs [6]. In addi-
tion to the basic coverage, the insured can buy supplemen-
tary insurance for the inpatient sector, which will provide 
them higher standard accommodation and treatment by chief 
physicians. Switzerland is divided into 26 cantons, which 
partially finance inpatient care services and are responsible 
for hospital planning. The canton of Zurich with almost 1.5 
million inhabitants in 2017 is the biggest canton and home 
to 25 listed hospitals and six non-listed hospitals. A listed 
hospital (which may be owned either publicly or privately) 
receives reimbursement from the cantons (at least 55% of the 
costs of each inpatient stay that is covered by the mandatory 
health insurance scheme), whereas non-listed hospitals are 
exclusively financed by out-of-pocket spending and supple-
mentary insurance. In 2012, Switzerland introduced a new 
hospital financing and payment system. On the financing 
side, the dual funding role by the mandatory health insur-
ance and the cantons was standardized across the country. 
On the payment side, a DRG-based reimbursement scheme 
was introduced for the acute inpatient sector. This reform 
put more pressure on the hospitals to provide treatments 
more efficiently because they now receive case-based lump-
sum payments rather than a fee for service reimbursement. 
Therefore, post-reform hospitals are expected to strive for 
more efficiency, e.g. by reducing length of stay. At the same 
time, there is a shift of surgical interventions from the inpa-
tient to the outpatient setting, which tends to reduce inpatient 
demand and potentially puts financial pressure on hospitals. 
Total spending for acute inpatient care services increased 
after the DRG implementation by 4.4% in 2012 and 2013, 
but the growth slowed down afterwards, with rates between 
–0.3% (2017) and +2.7% (2015 and 2016) [1].
Drivers of health care spending
Factors associated with the large increase in health care 
spending in high-income countries are still not well known. 
Most of the literature that aims to explain the spending 
increase looks at one specific factor and does not distinguish 
between service categories. Examples include the effect of 
demographic change in age structure and proximity to death 
(e.g. [7, 8]), the impact of technological progress in medi-
cine (e.g. [9, 10]), incentives faced by providers (supplier-
induced demand, e.g. measured by physician density as in 
[11] for Switzerland), and higher input prices. The latter 
is sometimes linked to Baumol’s cost disease (empirical 
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evidence for OECD countries including Switzerland see [12] 
and [13]), stating that input prices (wages for medical staff) 
increase over-proportionally in labour-intensive sectors such 
as health care compared to other sectors because productiv-
ity gains are only partly possible in these branches.
None of these approaches has taken a disease-based perspec-
tive, i.e. variation of these trends across diseases is not taken into 
account. Some studies have shown the usefulness of disease-
based analyses to investigate health care cost drivers. These stud-
ies used estimates of disease-specific spending that have been 
published for some countries (e.g. [14] for the United States, 
[15] for Norway, [16] for Switzerland). If disease-specific spend-
ing estimates are available at different points in time, they can 
be tracked to identify the changes in the associated factors at a 
more granular level. Most of the related literature is from and 
for the United States [17–22]. These studies found for different 
periods and different populations, that the increase in spend-
ing per treated case was the most important factor associated 
with the spending increase in the last three decades. However, 
they were mostly limited to two factors, such as the number of 
(treated prevalent) cases and costs per case.
From a methodological point of view, the two studies 
that are most closely related to our paper are the two recent 
decompositions by Zhai et al. for China [23] and Dieleman 
and colleagues for the United States [5]. Zhai et al. [23] 
used estimates of health care spending by disease in China 
for 1993 and 2012 and found that the most important factor 
associated with the increase was a strong rise in real costs 
per case. The effect of the change in the age structure was 
relatively small. Dieleman et al. [5] found similar results for 
the US. They found that spending per visit (outpatient) and 
spending per bed-day (inpatient) were the most important 
factors related to the increase in spending between 1996 and 
2013. For inpatient care, they also found a negative associa-
tion between spending and utilization, which was defined 
as bed-days per prevalent case, suggesting that the length of 
stay was reduced. They did, however, not explicitly include 
this factor. These two studies are able to show the relative 
importance of five basic factors and to estimate their con-
tributions by disease, using the same methodology and the 
same disease classification as the present study.
There are only few studies from comparable countries 
that investigated the drivers of inpatient care costs specifi-
cally. Wong et al. [24] assessed the impact of age and prox-
imity to death for disease-specific hospital spending using 
Dutch data and showed that for more lethal diseases, time 
to death is much more relevant than age per se. Most of the 
literature for Switzerland has focused on the (causal) effect 
of the recent DRG implementation on costs, utilization and 
quality. It was shown that after the reform in 2012 the return 
per inpatient case increased only slightly between 2012 and 
2015 (though again at a higher pace in 2016) [25]. The most 
important driver was the increase in the hospitalization rate 
(on average + 2.1% per year). One study found that age and 
sex standardized hospitalization rates in acute inpatient care 
in Switzerland did not change between 2009 and 2016 [26].
Data
Overview
The data set was provided by the Department of Health of the 
canton of Zurich. It holds detailed diagnostic and cost infor-
mation at the case level for all inpatient acute care episodes in 
the 25 hospitals listed in the canton of Zurich between 2013 
and 2017.1 Rehabilitation and psychiatric care facilities are not 
included in the data. There are between 208,000 and 227,000 
inpatient cases per year. A case is defined according to the 
case consolidation rules in the DRG system; with only few 
exceptions, any readmission for the same cause within 18 days 
since the first discharge is recorded in the same administrative 
case, i.e. a case can consist of multiple single stays. In what 
follows, the terms case and stay will be used interchangeably. 
Patients can be tracked over time and across hospitals. This 
enables the identification of recurrent encounters at the patient 
level. The data set provides information on patient’s demo-
graphics, hospitalization, insurance status, detailed diagnostic 
information with up to 50 diagnoses per stay according to the 
International Classification of Diseases, Volume 10 (ICD-10) 
and detailed case-specific cost data differentiated by 30–40 
cost types, depending on the year of observation.
Due to a change in the hospital accounting framework in 2013, 
we only used data from 2013 to 2017. Not all inpatient cases are 
reimbursed based on the DRG system. Between 2013 and 2015, 
about 600 cases per year were reimbursed based on a special pal-
liative care rate. The number of these cases fell to about 100 in 
2016 and 2017. We did not exclude non-DRG observations from 
the data since we were interested in costs rather than reimburse-
ment. For the age/sex group specific population numbers, we used 
the data from the Statistical Office of the canton of Zurich [28].
Data manipulations
We assigned each case to one of 42 age/sex groups: 21 age 
groups at five year age intervals except for the youngest (< 
1 year) and the oldest age group (> 95 years) by sex. Since 
we aimed at tracking the number of unique patients within 
1 The six non-listed hospitals that do not get governmental co-pay-
ments are not included since their financing is completely outside 
of the social health insurance system and the case costs are not pro-
vided to the cantonal authorities. The number (share) of total cases in 
these hospitals was 15,196 (6.8%) in 2013 and 14,165 (5.9%) in 2017. 
According to key data on the Swiss hospitals, the aggregate costs 
(share) amounted to 201.0 m CHF (7.0%) in 2013 and 207.5 m CHF 
(6.4%) in 2017 [27]. Hence the costs analyzed in this paper represent 
93% (2013) and 93.6% (2017) of total inpatient costs.
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each disease group for each year, we used the patient iden-
tifier based on the anonymized social insurance number 
that has been available since 2012. This variable showed 
missing values for all non-resident patients and for some 
Swiss residents. To fill these gaps, we used a second patient 
identifier. This identifier uniquely identifies patients within 
each hospital and year, but not across hospitals and years. 
Therefore, we slightly overestimate the number of unique 
patients because some of them might have been treated at 
different hospitals for the same disease in a given year. Some 
cases did not fall completely in one calendar year. Patients 
admitted at the end of a year but without discharge in the 
same year had no assigned diagnosis and were thus dropped. 
Some observations with entry and discharge date in the same 
calendar year were lacking a diagnosis and, thus, had to be 
excluded from the analysis. About five cases per year with 
entry in the last year and discharge in the following year 
(with total length of stay of more than 1 year) were also 
excluded from the analysis.
Cost categories
Our data contains rich cost information at the case level. 
The term costs refers to production costs of health services 
and not to the costs charged to the payer, which is based on 
the DRG case weight. This is a key innovation of the study, 
as to our knowledge, there has been no previous literature 
using the production cost information at the inpatient case 
level in Switzerland. With the introduction of the DRG sys-
tem in 2012, hospitals applied a unified accounting standard, 
ensuring consistent accounting rules across hospitals over 
the whole period. For each case, costs are recorded and dis-
tinguished by about 35 cost types. We aggregated the cost 
types into cost categories with the support of the Depart-
ment of Health. Five categories of costs are distinguished: 
physician costs, medical products costs (e.g. drugs), medical 
costs (e.g. nursing, diagnostics), other variable costs (e.g. 
accommodation, transport), and investment or infrastruc-
ture costs (depreciation). While the two categories ‘physi-
cian costs’ and ‘medical costs’ mainly consist of cost items 
recorded directly at the case level, the other cost categories 
comprise fixed costs that are generated through an allocation 
key. Most hospitals used the same accounting framework 
 (REKOLE® [29]) with strict definitions of the allocation 
key for each shared service to redistribute costs to cases. 
The key is closely linked to the actual resource use (e.g. 
minutes spent with a service) and is not just simply pro rata. 
 REKOLE® defines minimal accounting rules, but hospitals 
have the possibility to apply a more detailed cost distribution 
(e.g. by allocating costs according to minutes after reweight-
ing based on case severity or the intensity of service use). 
We assume that there has been no change in how fixed costs 
are distributed between 2013 and 2017. The costs comprise 
both the part covered by the mandatory as well as the sup-
plementary health insurance plan. Details about the mapping 
of cost types to cost categories as well as the record types 
are provided in the appendix.
The Global Burden of Disease Classification
The set of health conditions was defined based on the com-
prehensive and mutually exclusive Global Burden of Disease 
(GBD) classification. This classification defines three hierar-
chical levels of diseases. GBD Level 1 distinguishes between 
communicable and non-communicable diseases and injuries. 
Level 2 groups major diseases such as neoplasms or car-
diovascular diseases. Level 3 defines more specific diseases 
such as breast cancer or ischemic heart disease. The ICD-10 
codes entailed in our data were mapped to a slightly modi-
fied version of the GBD disease classification. We grouped 
the codes according to the classification used in the 2017 
Global Burden of Disease Study to obtain groups of dis-
ease codes [30]. To obtain a comprehensive and mutually 
exclusive classification, we made minor adjustments to the 
classification.2 We generally applied the level 3 classification 
with some exceptions. All five types of injuries as well as 
all eight types of communicable diseases were distinguished 
at level 2 only. The non-communicable diseases were clas-
sified at level 3, except for mental disorders and skin and 
subcutaneous diseases.3 We included two more categories 
for non-diseases/well care and non-distinctive codes. The 
adapted classification resulted in 100 diseases. The full list 
of diseases is provided in the appendix.
We allocated all the costs based on the primary diagnosis 
listed in each record. Accounting for concurrent conditions 
in cost-of-illness studies is essential and may impact cost 
estimates significantly [31]. Nevertheless, we did not include 
any secondary diagnoses in our analysis for three reasons. 
First, according to the Department of Health, the primary 
diagnosis coded has to be the diagnosis that caused the 
most amount of work for the hospital. Second, the impact of 
comorbidities may differ across different cost categories, i.e. 
it would be necessary to adjust each of the cost categories for 
the influence of further diagnoses. Third, there are methodo-
logical difficulties associated with such an adjustment, e.g. 
2 We proceeded in the same way as [16] and [14] in their decomposi-
tion of health care spending by diseases for Switzerland and the US. 
Besides the classification of disease groups, these studies defined 
additional conditions such as "well care" and the remaining category 
of non-distinctive codes to make the classification fully comprehen-
sive. The use of the same disease classification as previous studies 
guarantees comparability.
3 Mental disorders are not usually treated in the acute inpatient set-
ting considered here and skin and subcutaneous diseases showed low 
number of observations at the GBD level 3.
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the unintended incorporation of miscoding or the missing 
out of further comorbidities at the patient level.
Methods
Decomposition of aggregate measures
We used the Das Gupta method for the decomposition of 
aggregate measures [4] that was further extended for high 
numbers of factors [32]. The idea of this method is to cor-
rect for compositional effects when comparing multiple 
populations. The observed difference between two groups 
or two measures from the same group but from different 
points in time may be due to different characteristics in the 
two underlying populations. Our method of choice is rather 
mathematical than econometric such as the Oaxaca–Blinder 
decomposition approach [33, 34]. The method decomposes 
the difference between two points in time into its additive 
components. The contributions of single factors add up to 
100% of the total change and no residual remains. The inter-
action effects arising in the calculation of counterfactuals are 
distributed among the factors. The decomposition does not 
depend on the order in which the factors are included in the 
model. In the standard example, the aggregate measure is a 
product of the factors.
6‑Factor decomposition
We decomposed the change in disease-specific inpatient care 
costs between 2013 and 2017 into the changes caused by the 
six factors population size, population structure (captured in 
the model by the distribution of age/sex groups), inpatient 
treated prevalence (number of unique patients within each 
age/sex group), utilization (number of stays per prevalent 
patient), average length of stay (LOS), and costs per day of 
treatment. Treated prevalence and utilization are actually the 
two components of the admission rate; the first factor rep-
resents the number of patients treated for a certain disease 
(extensive margin), the second refers to the average number 
of stays of those who were treated (intensive margin). The 
costs per day component is a sum over the five cost catego-
ries (c). We exploited the fact that the aggregate costs in one 
year (2013 or 2017) can be re-written as the sum over the 
costs observed in each age/sex group (a) and disease (d) cell. 
These costs, in turn, are a product of the six factors.
The functional form is given by
The total cost difference by disease between 2013 and 2017 
is the sum of the age/sex group specific rate decompositions. 
Summing these values up over all diseases gives the total 
increase in costs between 2013 and 2017.
The 6-factor decomposition does not directly reveal the 
contribution of the change in costs per case. This key factor 
is instead captured by costs per day and length of stay. We 
ran a decomposition including only five factors to explicitly 
show the impact of the change in costs per case by disease.4
Decomposition by distribution
To allow for a more detailed view on what happens along 
the full distribution of costs per case, we created five groups 
of cases for each disease. All cases were allocated to one 
of these groups based on their location in the distribution 
of costs per case, and for 2013 and 2017 separately. The 
five thresholds for the cost groups were: <10th percentile 
(group 1), between the 10th and the 25th percentile (group 
2), between the 25th and the 75th percentile (group 3), 
between the 75th and the 90th percentile (group 4) and 
>90th percentile (group 5). The aim of this analysis was 
to investigate whether the importance of the factors differs 
across the distribution and which group of cases contributed 
most to the observed cost change.
For the distributional analysis, we applied a slightly dif-
ferent decomposition specification. As the total effect in the 
first specification is the sum over all age/sex group and dis-
ease-specific cells, the addition of a third dimension (distri-
bution of case costs) would lead to cells with potentially 
very few observations. In addition, the decomposition would 



























































within each distribution section by disease - which is not 
easily interpretable. We removed one dimension from the 
decomposition, namely the population structure. This means 
that in the second specification, the factors treated preva-
lence and utilization refer to the whole population (instead 
of to specific age/sex groups) for each disease. The two fac-
tors length of stay and cost per day are distribution group (g) 
specific and are "linked" to the three previous factors by 
including a technical factor case share ( = staysg,d
staysd
 ), which is 
the share of the number of cases in each distribution group 
of the total cases for this disease. By definition, this factor 
is equal to 10% for the distribution groups 1 (<10th percen-
tile) and 5 (>90th percentile) etc. The specification for the 
second part of our analysis thus reads as follows:
The results were obtained by applying the recently imple-
mented STATA package rdecompose [35].
Results
Descriptive statistics
Between 2013 and 2017, total acute inpatient costs for all 
diseases increased from CHF 2.67 billion to CHF 3.06 bil-
lion. This corresponds to an increase by CHF 394 million 
or 14.7%. The most important contributors to this rise were 
non-communicable diseases. More than 70% of the total cost 
increase was caused by these diseases, among which cardio-
vascular diseases had the biggest impact (22.5 percentage 
points), closely followed by neoplasms (18.2) and muscu-
loskeletal disorders (10.8). 28.3 % of the total cost increase 
was observed in the treatment of communicable diseases 
(10.7) and injuries (17.6).
Figure 1 illustrates the total costs by year stratified by 
age groups and gender. The highest absolute increase was 
observed between age 70 and 89 for both men and women. 
Even though the patients aged 0 represent the smallest age 
group, the costs and their absolute increase was higher than 





































The average costs per case increase with age, especially 
between age 40 and 80, as is shown in Fig. 2. The highest 
absolute increases in costs per case were found for the old-
est patients.
Table 1 shows the change in costs per case by cost cat-
egory as well as the change in average length of stay between 
2013 and 2017. In this period, mean costs per case increased 
by 5.2% to roughly CHF 13,500 in 2017. The largest growth 
rates were observed for physician costs (+ 7.4%) and other 
costs (+ 23.5%), but overall these two categories made up 
less than one-third of the total case costs in 2017. In both 
years, about half of the total costs per case were medical 
costs. Here, the growth rate was much lower at 3.4%. The 
only cost category that showed a decrease between 2013 
and 2017 was investment costs per case, but these costs 
accounted for less than 8% of the total costs per case in both 
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Fig. 2  Average costs per case by age groups, gender and year
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70.9% (musculoskeletal disorders) and 92.9% (well care) in 
2017. Across all conditions, it was 80.7% in 2017, slightly 
lower than in 2013 (81.3%). Moreover, there was an increase 
in the number of cases per year by 9.1%. However, this 
increase was partly offset by a decrease in the average length 
of stay. Table 4 in the appendix also shows these statistics 
by disease group (GBD level 2). Overall, we observe similar 
patterns across all disease groups, except for few diseases 
that showed a significant decrease in costs per case (e.g. 
respiratory infections, substance use disorders, unintentional 
injuries) or a significantly stronger increase (other infectious 
diseases). The magnitude of change for the cost categories 
differs across diseases.
6‑factor decomposition results
Plot a on the left-hand side of Fig. 3 shows the cost change in 
percent of 2013 costs associated with each of the six factors 
after decomposing the increase based on 100 diseases and 
42 age/sex groups. To assess the consistency of the factors’ 
relevance across the full period, we also show the associa-
tions resulting from similar decompositions for the periods 
Table 1  Summary statistics 
and growth rates for period 
2013–2017
Mean coefficients; sd in parentheses
2013 2017 Change 2013–2017
Total inpatient costs (bn CHF) 2.67 3.06 + 14.7%
Total Cost per case (CHF) 12804 13466 + 5.2%
(22744) (23427)
Physician costs per case (CHF) 2755 2959 + 7.4%
(4637) (5161)
Medical products costs per case (CHF) 1785 1893 + 6.1%
(5825) (5732)
Medical costs per case (CHF) 6315 6532 + 3.4%
(12999) (13516)
Other costs per case (CHF) 959 1183 + 23.5%
(1243) (1415)
Investment costs per case (CHF) 991 899 – 9.1%
(1609) (1346)
Length of stay (LOS) (d) 5.9 5.5 – 6.8%
(8.0) (7.3)
Cases 208438 227436 +9.1%
Fig. 3  Aggregated 6-factor 
decomposition results (2013–
2017) and detailed decomposi-
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2013–2014, 2013–2015, and 2013–2016. The increase in pop-
ulation size accounted for about one third of the total nomi-
nal increase. The changing population structure only led to a 
modest increase of total costs, as did the higher proportion of 
the population that was treated and the utilization factor, i.e. 
the number of stays per prevalent case. The reduction of the 
average length of stay was associated with a strong decline in 
costs. Costs would have decreased by 7.3% if only the length 
of stay had fallen to the level in 2017 and all the other factors 
had been as in 2013. The contribution of the costs per day 
factor is clearly positive (12.1%). Plot b on the right-hand side 
of Fig. 3 shows the contributions of the five cost types to the 
12.1% increase. The biggest contribution (5 percentage points 
of the total increase) can be observed for the medical cost 
category. This is not very surprising given that about half of 
the total costs per case are medical costs which have modestly 
increased between 2013 and 2017 (see Table 1).
There is some heterogeneity in the effect size across dis-
eases, as indicated by Fig. 4. In this figure, the results from 
the 100 disease-specific estimations are aggregated at the 
GBD level 2 (with 22 groups of diseases; mental disorders 
as well as the group of non-distinctive codes are not shown 
here). In the aggregation, no weighting takes place, i.e. the 
single factors’ contributions are summed up across all level 
3 diseases within each level 2 category. The size of a circle 
corresponds to the magnitude of the association, while the 
color shows the direction of change. A red circle is associ-
ated with a cost increase, whereas a green circle is associ-
ated with a cost decrease. The last column of black-rimmed 
circles summarizes the total cost increase between 2013 and 
2017 relative to the total costs in 2013. To put these relative 
changes into context, the bars on the right side of the fig-
ure show the aggregate costs for each disease in 2013. The 
number of treated patients as a share of each age/sex group’s 
population was associated with a cost increase of 7.3% for 
neoplasms, 24.9% for respiratory infections and tuberculosis 
and 28.8% for injuries of multiple body parts. The effect of 
this factor varied substantially across disease groups. For 
some communicable diseases, there was a reduction in the 
treated population (e.g. nutritional deficiencies and other 
infectious diseases), and also some expensive non-communi-
cable diseases such as musculoskeletal disorders and diges-
tive diseases showed small reductions associated with this 
factor. The utilization factor association was generally small, 
amounting to less than + / − 1% of the total cost increase 
for the majority of diseases. The two most important factors 
associated with the cost change were length of stay and costs 
per day. In general, the two effects were in opposite direc-
tion, with length of stay being negatively and cost per day 
being positively associated with the cost change between 
2013 and 2017. Only five disease groups showed a positive 
association of length of stay with costs, and only one disease 
Fig. 4  6-Factor decomposition results (2013–2017) and costs by disease in 2013 at GBD level 2
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group (sense organ diseases) showed a negative association 
of costs per day with costs. For very few diseases, including 
the most expensive disease group of cardiovascular diseases, 
there was a positive association of both factors with costs.
These heterogeneous effects become even more visible 
if we look at a more granular disease level. Figure 5 shows 
the decomposition for eleven single diseases from the GBD 
level 2 groups cardiovascular diseases (C), neoplasms (N) 
and musculoskeletal disorders (M), as well as diabetes mel-
litus. These diseases are shown in the order of their total 
costs in 2013 within their GBD level 2 group. Cardiovascu-
lar diseases, neoplasms and musculoskeletal disorders were 
the three most expensive disease groups in both 2013 and 
2017. Diabetes showed one of the strongest increase in costs 
(48.9%) across all diseases. Peripheral artery disease was an 
outlier among the cardiovascular diseases, as its aggregate 
costs decreased. This was mainly due to a strong negative 
association between the relative number of treated patients 
and costs. By contrast, stroke showed a strong cost increase, 
which was mainly due to an increase in costs per day. Within 
the neoplasms group, prostate cancer as well as tracheal, 
bronchus and lung cancer deserve special attention because 
of their significant cost increase (+ 59.1% and + 48.3%, 
respectively). Despite the reduction in length of stay for 
both conditions, the association between both the share of 
treated patients and the costs per day yielded a positive net 
cost change. Osteoarthritis showed an increase in the rela-
tive number of treated patients, whereas the converse held 
true for low back pain. For diabetes mellitus, we observe a 
positive association with costs for all six factors. This means 
that relatively more patients received an inpatient treatment, 
those patients had a higher utilization and longer stays with 
higher costs per day.
The complete results are provided in Tables 5 (level 2) 
and 7 (level 3) in the appendix.
The sum of the length of stay and the costs per day effect 
is roughly equal to the effect of costs per case. We checked 
this with a decomposition analysis including only five factors. 
The results are very similar, i.e. the costs per case effect is 
very close to the sum of the length of stay and the costs per 
day effect (see detailed results by disease in Tables 6 and 8 
in the appendix). While the average costs per case across all 
cases increased by 5.2%, there were decreases in some dis-
ease groups such as maternal and neonatal disorders (associ-
ated with a reduction of aggregate costs by – 1.2%), chronic 
respiratory diseases (– 3.8%) or skin and subcutaneous dis-
eases (– 7.1%). These diseases showed increasing costs per 
day, but the reduced length of stay offset this increase and 
yielded a negative contribution of costs per case.
Details for cost categories
In this section, we explore the cost per day factor in more 
detail by splitting it up into the five cost categories. Figure 6 
shows this decomposition result. This figure has the same 
structure and contains the same set of diseases as Fig. 4, but 
it shows the contribution of the five cost components in the 
first five columns and the costs per day instead of the total 
costs in the last column with black-rimmed circles. Also at a 
more granular level, the two most important cost factors are 
the physician and medical costs. Musculoskeletal disorders 
showed the strongest associations of these two categories 
with costs among the top three conditions (+ 5.2% and + 
6.8%, respectively). Neoplasms as well as diabetes and kid-
ney diseases had the strongest association of medical prod-
ucts costs (containing drugs) with aggregate costs (+ 4.6% 
and + 3.2%, respectively). Sense organ diseases also exhib-
ited an increase in this cost category, but they were one of 
the few examples for which the physician and medical costs 
were negatively associated with the cost change. Overall, the 
Fig. 5  6-factor decomposition 
results (2013–2017) and costs 
by disease in 2013 for selected 
diseases at GBD level 3
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medical products cost category varied substantially across 
diseases, with several communicable diseases showing a 
negative association with the total cost increase.
Decomposition across the distribution
The costs per day and the length of stay effect for each dis-
ease represent the sum over the effects within each age/sex 
group. Ignoring the age/sex dimension, but instead looking 
at different areas of the distribution of costs per case by dis-
ease allows us to investigate whether the least or the most 
expensive cases contributed more to the observed changes. 
Each factor’s effect can be interpreted as a weighted average 
over the group specific effect of five sections across the cost 
distribution. Since we applied a slightly different specifica-
tion for this analysis, the absolute values differ slightly com-
pared to the 6-factor decomposition. The general pattern is 
the same. We only focus on the contribution of each distribu-
tional section (< 10th percentile, between the 10th and 25th 
percentile, 25th–75th percentile, 75th–90th percentile, > 
90th percentile) to the total effect of each factor by disease. 
The contributions of each of the five sections to the total 
cost change by disease (at GBD level 2) are shown in the 
appendix (see Fig. 9). In general, the share of the 10% most 
expensive cases dominated the bottom of the distribution.
The factor decomposition isolated the association 
between the change in disease costs and both length of stay 
and costs per day by distributional sections. Figures 7 and 
8 show the contribution of each of the five distribution sec-
tions to the total effect. Diseases are ranked based on the 
total absolute increase associated with this factor. The dark 
blue bar represents the cost increase of the 10% most expen-
sive cases for each disease. We observe some heterogeneity 
in the effect of length of stay on the costs by disease. For 
cardiovascular diseases, the increase in the average length 
of stay is traced back only to the 10% most expensive cases. 
Similar patterns are observed for other diseases for which 
the length of stay increased on average5 (top of Fig. 7). There 
are more examples of diseases for which the average length 
of stay was not reduced for all the distribution sections, e.g. 
diabetes and kidney disease and neurological disorders. For 
diseases that showed a negative association along the whole 
distribution, the impact of the cases above the 75th percen-
tile was mostly dominant.
Fig. 6  Decomposition details 
for cost component, GBD level 
2
5 For few diseases with low costs such as HIV/AIDS and sexually 
transmitted infections, the specification that was chosen for the dis-
tributional analysis yielded a different sign for the factor’s association 
with costs. This is due to the fact that in the second specification, the 
overall effect is the sum over five distribution sections, whereas in 
the first specification, it is the sum over 42 (smaller) age/sex groups. 
Absolute differences are very small, however.
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The first decomposition specification including population 
structure showed a negative association between length of stay 
and costs per day. This was not necessarily true when looking 
at single sections of the distribution. There was an increase in 
the length of stay for the most expensive cases for other infec-
tious diseases, but this effect was reinforced by an increase in 
costs per day for the same group. For most diseases, there was 
an increase in costs per day along the whole distribution. Note-
worthy, there was a very small association of a reduction in 
the costs per day for the most expensive cardiovascular cases.
Conclusion and discussion
Summary
Given the rapid increase in health care spending in Switzer-
land in the last few years, it is pivotal to better understand the 
factors associated with this increase. This study was the first 
to decompose inpatient care costs by disease in Switzerland, 
using detailed cost data for the canton of Zurich, between 
2013 and 2017. It assessed the impact of six fundamental 
factors on the change of disease costs over time. The most 
important factor was the increase in the costs per day, which 
was partly offset by a reduction in the average length of stay. 
Population growth and age and sex structure were related to 
about half of the increase. A minor part was associated with 
an increase in the number of people treated relative to the 
population. This study contributed to the existing literature 
in three important ways. First, it included one additional 
factor in the decomposition specification, namely length of 
stay. Second, it further decomposed the costs per day factor 
into five cost components. Third, it reported results not only 
for the average, but also for the full cost distribution.
Discussion
The data we used does not reflect spending at prices charged 
to payers but production costs incurred by the hospitals. It is 
therefore a more objective measure of the resources needed to 
Fig. 7  Contribution of distri-
butional parts to total length of 
stay (LOS) effect by disease, 
GBD level2
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Fig. 8  Contribution of distribu-
tional parts to total cost per day 
effect by disease, GBD level2
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provide treatment for each disease than spending. However, the 
cost changes observed in this study do not necessarily corre-
spond to the actual health care spending changes by disease, 
since hospitals might either realize profits or the costs by disease 
might not perfectly correspond to the spending for the diseases.
Although we used data at the individual level, an aggre-
gation of the cost data at the disease and age/sex group 
level was appropriate for the question we aimed to answer. 
Decomposition methods usually used with individual level 
data, i.e. Oaxaca and Blinder type decompositions [33, 34], 
are of limited use here since they aim at explaining the mean 
outcome (in our case mean costs per day or case) and thus 
ignore the factors leading to the aggregate change such as 
population growth or utilization. One strength of our study 
lies in its ability to separate the propensity to be treated from 
the utilization as well as the intensity and price of treatment 
(captured by length of stay and costs per day).
The observed positive association between population 
structure and costs is due to the fact that patients in higher 
age groups exhibit more stays and higher costs per case. It 
has been shown for Switzerland that costs per patient and 
hospital days per person in the inpatient sector increase sig-
nificantly beyond the age of 60 [36]. Since we controlled for 
other factors, the cost increase that is linked to a change in 
population structure is small.
Several reasons may explain the increase in the share 
of people being treated, which was associated with a cost 
increase of 1.9%. The first one might be supplier-induced 
demand. A recent study for Germany has shown that the 
steady increase in hospital admissions can be explained only 
partially by demand-side factors such as time-to-death and 
morbidity; about 80% is accounted for by supply-side effects 
resulting from the DRG reimbursement system [37]. The sec-
ond reason is linked to technological progress: new diagnos-
tic and treatment options allow more patients to be success-
fully treated, which possibly leads to better health outcomes 
[38]. The third reason is a more technical one. We measured 
the treated prevalence as the share of unique patients within 
each age/sex group. Since some patients live outside of the 
canton of Zurich, but this information was not accessible 
to us, the factor is also influenced by inter-cantonal patient 
migration and might thus be slightly biased. The share of the 
net patient migration has increased from 9.5 to 10.7% of the 
stays between 2013 and 2017 [39]. We can therefore not rule 
out that for some diseases, part of the effect of the treated 
factors is driven by patients coming from other cantons. A 
fourth explanation is the underlying disease prevalence: if 
more people suffer from a disease, the number of treated 
patients is likely to increase too. However, our study was not 
able to capture the health-related needs of the patients and 
thus ignored the fact that some diseases become more or less 
prevalent. The studies by Dieleman et al. [5] and Zhai et al. 
[23] included age/sex-specific prevalence estimates for each 
disease from the GBD project in their decompositions and 
reported utilization per prevalent case instead of per treated 
patient. Even though national prevalence estimates are also 
available for Switzerland from the GBD project, we did not 
include these in our analysis of sub-national data. Since we 
only focus on one health care sector, our two factors treated 
and utilization provide policy makers more easily interpret-
able results than utilization per (clinically) prevalent case.6 
For some communicable diseases and injuries, we observed 
a reduction in the share of treated patients. This might be 
due to a shift from inpatient to outpatient treatments. Despite 
this development, the number of treated people has further 
increased for most diseases. This suggests that surgeries in 
the inpatient setting do not decrease to the same extent as the 
outpatient treatments increase [42].
The observed decrease in the length of stay and the increase 
in the utilization factor might both be linked to the implementa-
tion of the DRG reimbursement system. Hospitals have been 
incentivized to discharge patients early and to produce more 
stays (e.g. [43] for the United States). Previous research for 
Switzerland provided evidence that the system change led to an 
increase in hospital readmissions [44]. Readmissions within 18 
days of treatment are, however, already included in our records 
and do not constitute an additional stay, i.e. the utilization fac-
tor as defined here captures the increase in stays per patient on 
top of that. The differentiation between the number of stays 
per patient and the length of stay thus proves to be relevant, 
as the effects go in opposite directions. Utilization defined as 
number of days per patient like in [5] captures both effects at the 
same time. Furthermore, our study confirms previous evidence 
for Switzerland, as it found a strong association between the 
reduced length of stay and costs [45]. The heterogeneity of the 
length of stay factor association across diseases might indicate 
different levels of efficiency margins for different diseases.
The reduction in length of stay was offset by an even 
higher increase in costs per day.7 This result is in line with 
6 Moreover, the estimates are only partially reasonable, which is 
mainly because they are not in every case based on Swiss data, but 
inferred from data from neighbouring countries. One example is the 
prevalence rate of diabetes in 2017, which is estimated at 11.1%. This 
is too high compared to recent evidence [40, 41]. Second, they are not 
available at the sub-national level.
7 Only a part of costs (19.3% in 2017) represented direct costs, i.e. 
cost items directly assigned to the case (e.g. physicians’ time with 
the patient and drugs). The rest was fixed costs from services that are 
shared by all patients (e.g. operating rooms and imaging). However, 
it is important to note that the term “fixed” does not mean that costs 
are simply apportioned across cases. The share allocated to each case 
is closely linked to its actual resource use. Fixed costs are assigned 
based on the time the service was used (e.g. operation room) or other 
measures of intensity. Hospitals also have the possibility to weight the 
costs by disease severity or service use intensity prior to allocation. 
Hospital accounting experts confirmed that the cost allocation clearly 
reflects actual resource use for most cost types, which is also in line 
with the primary goal of the accounting, namely the reporting of case-
specific costs for DRG calculations.
Factors related to the change in Swiss inpatient costs by disease: a 6-factor decomposition 
1 3
the results by Dieleman et al. for the US, who found an 
increase in costs per hospital day and a reduction in bed-
days per prevalent case [5]. The reason might be a compres-
sion of (more intensive) treatment into a shorter period of 
time. The relative size of the two competing effects of length 
of stay (negative) and costs per day (positive) in our study 
(7.3%/12.1% = 60%) is the same as the ratio of bed-days 
per patient and costs per day in [5]. This accordance is sur-
prising, even though they defined the utilization term in a 
slightly different way than we did. The costs per day factor 
likely captures to some extent higher input prices, e.g. due 
to technological progress in drugs and higher wages, and 
an increase in treatment intensity, e.g. due to technologi-
cal progress or supplier-induced demand. This is, however, 
only likely in the case that the additional treatment leads to 
higher reimbursement for the hospital. A significant part of 
the increase in costs per day is probably due to an increase 
in input prices for medical staff. Our costs per day decom-
position showed that 8.1 of the 12.1%-points cost increase 
association was due to medical and physician costs, two 
categories mainly consisting of labor expenses. The Swiss 
statistics on hospitals (Krankenhausstatistik) by the Federal 
Statistical Office reports that the total wage bill in general 
hospitals in the canton of Zurich increased by 13% between 
2013 and 2017 [2]. The highest increase was observed for 
physicians’ salaries. Their share of the total wages increased 
from 24.0 to 25.7%, which is equal to a rise of the wage 
sum for physicians by 21% in the 4 years period. A similar 
focus on the sources of increasing costs per inpatient case 
was taken previously by a study in the United States which 
showed that supplies and devices, room and board, intensive 
care and operating rooms as well as drugs contributed to 
more than 75% of the increase in costs per case between 
2001 and 2006 [46].
Accounting for length of stay as well as costs per day is 
important. However, policy makers are more likely to be 
interested in their joint effect, i.e. costs per case. Despite 
a modest overall increase in average costs per case, aver-
age costs decreased for some diseases. This is surprising, 
as input costs, and particularly wages of hospital personnel, 
increased substantially over the study period.
Our analysis of distributional aspects revealed that for 
most diseases, the 10% most expensive cases showed the 
highest contribution to the factor associations. However, 
it also showed that the direction of the effect might dif-
fer across the distributional sections and by disease. Only 
recently, the literature aiming at identifying cost drivers has 
started to look at other measures than just the average [47, 
48]. DeMeijer et al. [48] used Dutch data and showed that 
the impacts of various explaining variables measured at the 
patient level differed across the spending distribution. For 
hospital spending, growth was found to be largest in the 
middle of the distribution. In contrast to their study, we did 
not use an individual-level decomposition, but our results 
provide insights at the disease level.
Limitations
This study has several limitations. First, we did not account 
for comorbidities in the allocation of costs to diseases. A 
recent study showed that spending estimates by disease are 
affected by the choice of allocation method [31]. About 19% 
of the cases in our data do not include any secondary diagno-
ses and would not be affected by a comorbidity adjustment; 
about 25% show six or more comorbidities. Among those 
cases with secondary diagnoses, the first coded secondary 
diagnosis was aggregated into the same disease group by our 
algorithm as the main diagnosis in 31% of the cases (22% 
for the second, 16% for the third). In such cases there is no 
need for a comorbidity adjustment. For a substantial part 
of the cases, however, there are coded comorbidities other 
than the main diagnosis, which would potentially require the 
assignment of costs to more than one disease. The second 
limitation of our study is the short time period. This is due 
to data quality and consistency across years. It would be 
interesting to see in the future whether similar patterns are 
observed over time even several years after the introduction 
of the DRG payment system. Third, due to data availability, 
the study only covers one health care sector. A comparison 
across outpatient and inpatient would be highly relevant for 
policy making. Fourth, the observed positive association of 
the costs per day factor with aggregate disease costs does 
not necessarily mean treatments were not cost-effective. Our 
study was not able to account for outcome quality.
Policy implications and future research
A better understanding of the epidemiological, technological 
and demographic trends on health care costs may be particu-
larly useful for a sound definition of global spending budgets 
currently discussed in Switzerland. Effective cost contain-
ment policies require reliable estimates of the key factors 
influencing costs at a very granular level such as specific dis-
eases. The majority of the cost increase was due to only three 
groups that caused an increasing health and cost burden and 
should be monitored carefully. Furthermore, it is important 
to know the consequences of a change in the hospital pay-
ment system for health care utilization. Our study suggests 
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that the number of cases per treated (in)patient within each 
disease group is increasing, which would somehow conflict 
with the goal to increase efficiency in hospitals.
Future research should include other health care sectors 
to investigate whether there has been a shift to outpatient 
treatments and if yes to what extent and for which diseases. 
It is further important to research the reasons for the factor 
associations we found, e.g. the increased number of treated 
inpatients relative to the population and the increased num-
ber of stays per (in)patient over time. In addition, it would 
be interesting to assess whether the additional health care 
use is due to increased care needs or due to hospital-induced 
demand. Accounting for the cost impact of comorbidities is 
a very important and demanding task for future research. 
Some regression-based approaches have recently been pro-
posed by the literature to adjust for concurrent diseases at 
the patient or the encounter level [49, 50]. Our framework 
could also be used to assess the impact of lower length of 
stay on treatment quality at the level of specific diseases. 
The reduction in length of stay is only desirable if there are 
no “bloody exits” associated with worse health outcomes. 
Finally, expanding the analysis to more than just average 
effect has shown how important it is to have a closer look 
at which cases contributed most to the cost increase. It is 
therefore vital to include distributional aspects into future 
cost-of-illness studies and other research looking at drivers 
of health care spending.
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Appendix
See Tables 2, 3, 4, 5, 6, 7, 8 and Fig. 9.
Table 2  Cost types included in cost categories
a Direct costs (i.e. cost items directly allocated at the case level)
Cost category Cost types included
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Other case-specific  costsa
Investment costs Capital costs (depreciation)
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Table 3  Modified disease classification with three disease levels according to the Global Burden of Disease study
GBD Level 1 GBD Level 2 GBD Level 3
Communicable diseases HIV/AIDS and sexually transmitted infections
Respiratory infections and tuberculosis
enteric infections
neglected tropical diseases and malaria
other infectious diseases
maternal and neonatal disorders
nutritional deficiencies





Colon and rectum cancer
Liver cancer
Gallbladder and biliary tract cancer
Pancreatic cancer
Larynx cancer
























Non-rheumatic valvular heart disease
Cardiomyopathy and myocarditis




Other cardiovascular and circulatory diseases
Chronic respiratory diseases Chronic obstructive pulmonary disease
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Table 3  (continued)
GBD Level 1 GBD Level 2 GBD Level 3
Pneumoconiosis
Asthma
Interstitial lung disease and pulmonary sarcoidosis
Other chronic respiratory diseases
Digestive diseases Cirrhosis and other chronic liver diseases
Upper digestive system diseases
Appendicitis
Paralytic ileus and intestinal obstruction
Inguinal, femoral, and abdominal hernia
Inflammatory bowel disease
Vascular intestinal disorders
Gallbladder and biliary diseases
Pancreatitis
Other digestive diseases








Substance use disorders Alcohol use disorders
Drug use disorders
Diabetes and chronic kidney diseases Diabetes mellitus
Chronic kidney disease
Acute glomerulonephritis
Skin and subcutaneous diseases
Sense organ diseases Blindness and vision impairment
Age-related and other hearing loss
Other sense organ diseases






Other non-communicable diseases Congenital birth defects
Urinary diseases and male infertility
Gynecological diseases
Hemoglobinopathies and hemolytic anemias
Endocrine, metabolic, blood, and immune disorders
Oral disorders
Sudden infant death syndrome
Injuries Transport injuries
Unintentional injuries
Self-harm and interpersonal violence
Injury of one body part
Injury of multiple body parts
Well care
Non-distinctive codes
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Cardiovascular diseases 5.7 2.6 2 0.6 0.2 8.5 19.7 450
Musculoskeletal disorders 5.6 1 − 2.9 0.1 − 10.7 18.3 11.4 373
Neoplasms 5.8 1.4 7.3 3 − 11 13.2 19.8 362
Injury of one body part 5.6 1.5 − 3.6 0.9 − 2.8 11.8 13.4 258
Other non−communicable diseases 5.7 0.6 9.6 2 − 10.8 10.7 17.8 233
Digestive diseases 5.4 1.2 − 1.4 0.3 − 11.5 11.4 5.3 221
Well care 5.4 − 0.1 −  3.2 −0.4 − 9.2 12.6 5 116
Maternal and neonatal disorders 5.8 0.3 13 1.7 − 8.3 7.1 19.5 105
Other infectious diseases 5.5 1.9 − 31.7 − 0.6 9.4 21.9 6.4 90
Injury of multiple body parts 6.3 1.5 28.8 1.6 − 12.5 16.1 41.8 88
Chronic respiratory diseases 5.5 0.9 6.9 2.1 − 8.9 5.1 11.6 61
Neurological disorders 5.6 1.1 0 1.8 − 6.7 11.4 13.2 58
Respiratory infections and tuberculosis 6 2.7 24.9 0.2 − 12.9 6.9 27.8 52
Non−distinctive codes 5 1.9 − 10.2 0.2 − 19.1 10.9 − 11.2 46
Skin and subcutaneous diseases 5.3 1.4 2.7 − 0.9 − 8.2 1.2 1.4 37
Sense organ diseases 5.3 1.7 − 12.5 1.1 6.2 − 2.1 − 0.3 28
Mental disorders 5.8 2.1 0.6 2.2 − 3.1 14.6 22.3 28
Diabetes and kidney diseases 5.7 1.6 − 1.6 3.8 − 6.3 16.2 19.4 24
Unintentional injuries 4.8 0.9 − 15.3 0.6 − 20 10.3 − 18.6 12
Enteric infections 5.5 2 0.4 − 0.9 − 5.5 10.2 11.7 12
Substance use disorders 5.5 − 0.2 12.5 2.5 − 49.4 26.6 − 2.5 9
Nutritional deficiencies 5.4 2.2 − 6.6 − 1.1 1.7 2.7 4.3 4
HIV/AIDS and sexually transmitted infections 4.9 − 0.8 − 11.9 − 0.1 − 14.3 16.7 − 5.5 3
Neglected tropical diseases and malaria 5.9 − 1.3 − 12.8 5.8 15.3 13.6 26.4 1
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Cardiovascular diseases 5.7 2.6 1.9 0.5 8.9 19.7 450
Musculoskeletal disorders 5.6 1 − 2.9 0.1 7.6 11.4 373
Neoplasms 5.8 1.4 7.2 3 2.4 19.8 362
Injury of one body part 5.6 1.5 − 3.6 0.9 9 13.4 258
Other non−communicable diseases 5.7 0.6 9.7 2 − 0.1 17.8 233
Digestive diseases 5.4 1.2 − 1.4 0.3 − 0.1 5.3 221
Well care 5.4 − 0.1 − 3.2 − 0.4 3.3 5 116
Maternal and neonatal disorders 5.8 0.3 13 1.7 − 1.2 19.5 105
Other infectious diseases 5.5 2 − 32 − 0.6 31.6 6.4 90
Injury of multiple body parts 6.3 1.5 28.8 1.5 3.7 41.8 88
Chronic respiratory diseases 5.5 0.9 6.9 2.1 −3.8 11.6 61
Neurological disorders 5.6 1.1 − 0.1 1.8 4.8 13.2 58
Respiratory infections and tuberculosis 6 2.7 24.9 0.2 − 6 27.8 52
Non−distinctive codes 5 2 − 9.8 0.2 − 8.5 − 11.2 46
Skin and subcutaneous diseases 5.3 1.4 2.7 − 0.9 − 7.1 1.4 37
Sense organ diseases 5.3 1.7 − 12.4 1.1 4 − 0.3 28
Mental disorders 5.8 2.1 0.6 2.2 11.6 22.3 28
Diabetes and kidney diseases 5.7 1.6 − 1.3 3.9 9.5 19.4 24
Unintentional injuries 4.8 0.9 − 15.2 0.7 − 9.7 − 18.6 12
Enteric infections 5.5 2 0.5 − 0.9 4.6 11.7 12
Substance use disorders 5.2 − 0.1 10.8 2.5 − 20.9 − 2.5 9
Nutritional deficiencies 5.3 2.2 − 6.8 − 1.4 4.9 4.3 4
HIV/AIDS and sexually transmitted infec-
tions
4.9 − 0.9 − 10.9 0.4 0.9 − 5.5 3
Neglected tropical diseases and malaria 5.9 − 1.3 − 11.4 6.1 27 26.4 1
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Cardio Other cardiovascular and 
circulatory diseases
5.9 2.7 − 1.8 1.7 5.1 11 24.6 125.3
Cardio Ischemic heart disease 5.6 2.5 2.2 − 0.2 − 1.5 3 11.5 121.1
Cardio Stroke 6.2 2.9 12 1.6 − 2.2 17.2 37.7 96.7
Cardio Peripheral artery disease 5.2 3 −  22.3 0.1 1.7 8.1 − 4.2 32.6
Cardio Aortic aneurysm 5.6 2.4 1.3 − 1.2 20.1 − 15.7 12.4 28.5
Cardio Atrial fibrillation and 
flutter
7.4 3.1 51 3 −15.5 34.3 83.2 16.2
Cardio Cardiomyopathy and 
myocarditis
4.5 0.2 4.8 − 7.4 − 25.8 − 1.4 − 25 12.4
Cardio Rheumatic heart disease 2.9 1.5 − 60 − 0.1 − 14.1 − 8.5 − 78.3 9.6
Cardio Hypertensive heart 
disease
4.8 2.8 − 17.4 − 1 − 28.6 19.1 − 20.2 3
Cardio Endocarditis 6.1 3.1 31.2 0 3.2 18.4 62.1 4.5
Musculoskeletal Other musculoskeletal 
disorders
5.5 0.8 − 7.3 0.3 − 7.7 17.6 9.2 254.8
Musculoskeletal Osteoarthritis 5.7 1.6 8.4 − 0.2 − 17.9 20.5 18.1 105.8
Musculoskeletal Low back pain 5.3 1.1 − 10.2 − 0.4 − 12.8 17.3 0.2 9.6
Musculoskeletal Rheumatoid arthritis 4.3 0.6 − 14.9 − 4.3 − 17.4 − 1.1 − 32.8 1
Musculoskeletal Gout 5.2 3.7 − 7 − 0.5 − 2 2.6 2.1 1.5
Neoplasms Other neoplasms 5.5 1 1.9 1.5 − 12.9 13.1 10.2 62
Neoplasms Colon and rectum cancer 5.7 2.3 13.3 3.9 − 23.6 15.7 17.3 34.5
Neoplasms Other malignant neo-
plasms
5.3 0.7 2 3.7 − 22.8 7.3 − 3.9 29.7
Neoplasms Breast cancer 5.4 0 − 5.9 − 0.1 − 2.5 7.7 4.7 24.6
Neoplasms Leukemia 5.8 0 − 4.4 5.6 − 8.2 16.5 15.3 24.5
Neoplasms Tracheal, bronchus, and 
lung cancer
6.5 1.6 25.8 − 0.5 − 1.9 16.7 48.3 24.2
Neoplasms Prostate cancer 6.7 2.9 34.7 3.8 − 16.4 27.4 59.1 20.6
Neoplasms Bladder cancer 6.2 3.8 18.1 2.5 − 6.1 14.8 39.4 15
Neoplasms Non−Hodgkin lym-
phoma
6.2 1 3.9 11.9 − 4.3 13.1 31.9 14
Neoplasms Brain and nervous sys-
tem cancer
5.6 1.1 11.3 4.3 − 14.5 1.7 9.5 12.7
Neoplasms Pancreatic cancer 5.8 1.9 17.7 7.6 − 16.7 7.8 24.1 11.4
Neoplasms Ovarian cancer 5.2 0.3 5.7 − 1.7 −14.3 4.2 − 0.6 11.3
Neoplasms Esophageal cancer 4.9 1.9 − 23.2 0.1 − 13.2 16.9 − 12.5 10.7
Neoplasms Stomach cancer 6.5 1.9 31.5 − 9.5 − 5.8 18 42.5 6.9
Neoplasms Lip and oral cavity 
cancer
6.2 1.8 4.4 2.8 11.6 9.6 36.4 6.8
Neoplasms Liver cancer 6.6 2.6 22.7 9.1 − 0.4 15.4 56 6.7
Neoplasms Multiple myeloma 5.5 1.1 4.4 2.7 − 15.9 15.9 13.8 6.4
Neoplasms Kidney cancer 6.5 2.9 29 5.6 − 14.9 17.1 46.2 6.3
Neoplasms Uterine cancer 5.4 0.5 − 1.4 8.7 − 17.5 10.2 5.9 5.2
Neoplasms Non−melanoma skin 
cancer
5.4 3.8 4.6 − 9.2 − 1.1 1.2 4.7 4.6
Neoplasms Malignant skin mela-
noma
5.9 1.7 3.8 4.8 8.6 4.7 29.5 4.2
Neoplasms Other pharynx cancer 5.4 2 − 37.6 4.3 11.3 17.1 2.6 3.5
Neoplasms Cervical cancer 5.9 0.2 − 4 6.4 − 3.6 17.1 21.9 3.2
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Neoplasms Thyroid cancer 6.4 0.6 5.7 8 − 16.8 34.6 38.4 3
Neoplasms Gallbladder and biliary 
tract cancer
6 3.3 − 9.6 15.9 − 2.1 16.3 29.7 3
Neoplasms Hodgkin lymphoma 5 − 0.6 − 2.4 3.7 24.7 −3.2 27.2 1.5
Neoplasms Larynx cancer 5.5 2.6 − 18.7 12.7 19 − 5.9 15.2 1.5
Neoplasms Testicular cancer 6.2 − 1.3 4.4 9.2 10.5 13.5 42.6 1.2
Neoplasms Nasopharynx cancer 2.7 1.1 − 11.2 2.4 − 6.2 − 9.4 − 20.5 0.4
Neoplasms Mesothelioma 5.6 1.5 − 3.9 − 3.8 − 11.2 19.3 7.5 2.8
OtherNCD Endocrine, metabolic, 
blood, and immune 
disorders
5.5 0.4 15.5 1.1 − 21.6 9.3 10.2 64.8
OtherNCD Urinary diseases and 
male infertility
6.3 2.2 26.8 1.2 − 4.6 11.1 43.1 59.4
OtherNCD Congenital birth defects 5.5 0.7 − 6.7 5.9 − 1.9 5.9 9.3 52.5
OtherNCD Gynecological diseases 5.3 − 1 − 7 − 0.5 − 14.1 17.8 0.6 43.8
OtherNCD Oral disorders 6.5 − 1.7 36.7 2.9 − 8.3 15.2 51.3 7.9
OtherNCD Hemoglobinopathies and 
hemolytic anemias
5.4 1.1 1.5 3.3 − 13.3 4.5 2.6 4.9
Digestive Other digestive diseases 5.3 1.3 − 5.3 − 0.4 − 12.9 12.5 0.5 61.4
Digestive Inguinal, femoral, and 
abdominal hernia
5.6 1.4 6.2 0 − 7.6 7.6 13.2 34
Digestive Gallbladder and biliary 
diseases
5.4 1.5 1.5 − 1.7 − 14.5 13.2 5.4 33.7
Digestive Appendicitis 5.5 − 0.4 − 1.6 − 1.2 − 12.4 17 7 18.8
Digestive Cirrhosis and other 
chronic liver diseases
5.2 0.6 − 12.2 4.7 − 6.3 4.4 − 3.7 18.8
Digestive Paralytic ileus and intes-
tinal obstruction
4.9 2.1 − 15 1.8 − 15.1 10.1 − 11.1 17.5
Digestive Upper digestive system 
diseases
5.5 1.6 − 1.7 1.1 − 8.2 10.5 8.8 14.9
Digestive Pancreatitis 5.8 0.8 17.6 − 1 − 5.2 9.9 27.9 9.9
Digestive Inflammatory bowel 
disease
5.5 0.2 −10.6 5 − 0.9 12 11.1 7.9
Digestive Vascular intestinal 
disorders










5.4 2.4 − 3.6 4.7 − 4.9 3 6.9 19.7
Chronic respira-
tory
Interstitial lung disease 
and pulmonary sar-
coidosis
5.7 2.5 19.8 10.7 − 18 5.9 26.7 3.9
Chronic respira-
tory
Asthma 5.8 1.1 − 16.1 5.8 4.5 20.1 21.2 1.3
Chronic respira-
tory
Pneumoconiosis 1.9 0.9 − 6.7 − 6.7 − 6.7 − 6.7 − 24 0.1
Neurological Epilepsy 5.5 0 3.8 2.1 − 18.5 15.8 8.8 21.5
Neurological Other neurological 
disorders
5.9 1.1 − 1.4 1.5 8.6 9.2 24.9 21.4
Neurological Alzheimer’s disease and 
other dementias
5.3 3.3 4.4 2.1 − 24.4 10.6 1.3 6.5
Neurological Parkinson’s disease 5.2 2.7 − 3.9 2.7 − 0.9 6.4 2.3 5.6
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Neurological Multiple sclerosis 4.5 0.7 − 12 − 7 − 3 − 1.8 − 18.6 1
Neurological Motor neuron disease 4.7 2.6 − 25.6 3.7 − 8.9 6.3 − 17.1 0.9
Neurological Headache disorders 6.7 − 0.4 34.6 3.6 1.6 14 60 0.8
Skin and subcu-
taneous
Skin and subcutaneous 
diseases
5.3 1.4 2.7 − 0.9 − 8.2 1.2 1.4 36.6
Sense organ Blindness and vision 
impairment
5.4 2 − 14.6 2.8 7.6 0 3.1 18.2
Sense organ Other sense organ 
diseases
5.1 1.2 − 8.6 − 2  3.6 − 6.2 − 6.7 9.8
Diabetes Chronic kidney disease 5 1 −18.8 1.3 − 18.4 21.7 − 8.2 12.8
Diabetes Diabetes mellitus 6.4 2.3 17.2 6.2 6.8 9.9 48.9 11.4
Diabetes Acute glomerulone-
phritis
3.9 1.8 44.1 44.1 44.1 44.1 182 0.1
Substance use Alcohol use disorders 5.4 0.4 5 4.8 − 21 11.5 6.2 6
Substance use Drug use disorders 5.7 − 1.2 27.3 − 2 − 106 56.8 − 19.6 3
Mental Mental disorders 5.8 2.1 0.6 2.2 − 3.1 14.6 22.3 27.6
Communicable maternal and neonatal 
disorders
5.8 0.3 13 1.7 − 8.3 7.1 19.5 104.6
Communicable other infectious diseases 5.5 1.9 − 31.7 − 0.6 9.4 21.9 6.4 89.8
Communicable Respiratory infections 
and tuberculosis
6 2.7 24.9 0.2 − 12.9 6.9 27.8 52.1
Communicable enteric infections 5.5 2 0.4 − 0.9 − 5.5 10.2 11.7 11.7
Communicable nutritional deficiencies 5.4 2.2 − 6.6 − 1.1 1.7 2.7 4.3 3.8
Communicable HIV/AIDS and sexually 
transmitted infections
4.9 − 0.8 − 11.9 − 0.1 − 14.3 16.7 − 5.5 2.9
Communicable neglected tropical dis-
eases and malaria
5.9 − 1.3 − 12.8 5.8 15.3 13.6 26.4 0.9
Injuries Injury of one body part 5.6 1.5 − 3.6 0.9 − 2.8 11.8 13.4 257.7
Injuries Injury of multiple body 
parts
6.3 1.5 28.8 1.6 − 12.5 16.1 41.8 88.4
Injuries Unintentional injuries 4.8 0.9 − 15.3 0.6 − 20 10.3 − 18.6 12.5
Well care Well care 5.4 − 0.1 − 3.2 − 0.4 − 9.2 12.6 5 115.7
Non-distinctive Non−distinctive codes 5 1.9 − 10.2 0.2 − 19.1 10.9 − 11.2 46.1
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Cardio Other cardiovascular and 
circulatory diseases
5.9 2.7 −1.8 1.7 16.2 24.6 125.3
Cardio Ischemic heart disease 5.6 2.5 2.2 −0.2 1.5 11.5 121.1
Cardio Stroke 6.2 2.9 12 1.7 15 37.7 96.7
Cardio Peripheral artery disease 5.2 3 −22.3 0 9.9 −4.2 32.6
Cardio Aortic aneurysm 5.5 2.4 1.1 −1.4 4.8 12.4 28.5
Cardio Atrial fibrillation and flutter 7.3 3.1 50.1 3.1 19.5 83.2 16.2
Cardio Cardiomyopathy and myo-
carditis
4.6 0.2 4.7 −7.9 −26.6 −25 12.4
Cardio Rheumatic heart disease 2.9 1.5 −60.1 −0.6 −21.9 −78.3 9.6
Cardio Endocarditis 6 2.7 25.8 −1.1 28.8 62.1 4.5
Cardio Hypertensive heart disease 4.7 2.8 −17.4 −0.9 −9.5 −20.2 3
Musculoskeletal Other musculoskeletal 
disorders
5.5 0.8 −7.2 0.3 9.9 9.2 254.8
Musculoskeletal Osteoarthritis 5.7 1.6 8.4 −0.1 2.6 18.1 105.8
Musculoskeletal Low back pain 5.3 1.1 −10 −0.4 4.4 0.2 9.6
Musculoskeletal Gout 5.2 3.8 −6.3 −0.3 −0.4 2.1 1.5
Musculoskeletal Rheumatoid arthritis 4.3 0.5 −13.4 −4.5 −19.7 −32.8 1
Neoplasms Other neoplasms 5.5 1 1.9 1.5 0.3 10.2 62
Neoplasms Colon and rectum cancer 5.7 2.3 13.2 4 −7.8 17.3 34.5
Neoplasms Other malignant neoplasms 5.2 0.6 2 3.6 −15.3 −3.9 29.7
Neoplasms Breast cancer 5.4 0 −5.9 −0.1 5.2 4.7 24.6
Neoplasms Leukemia 5.8 0 −5 5.5 9 15.3 24.5
Neoplasms Tracheal, bronchus, and lung 
cancer
6.5 1.6 25.8 −0.5 14.9 48.3 24.2
Neoplasms Prostate cancer 6.7 2.9 34.6 3.8 11.1 59.1 20.6
Neoplasms Bladder cancer 6.2 3.8 18.1 2.5 8.8 39.4 15
Neoplasms Non−Hodgkin lymphoma 6.2 1 3 10.6 11.1 31.9 14
Neoplasms Brain and nervous system 
cancer
5.6 1.1 11.3 4.3 −12.8 9.5 12.7
Neoplasms Pancreatic cancer 5.8 1.9 17.8 7.7 −9.1 24.1 11.4
Neoplasms Ovarian cancer 5.2 0.3 5.7 −1.8 −10.1 −0.6 11.3
Neoplasms Esophageal cancer 4.9 1.9 −23.3 0.1 3.8 −12.5 10.7
Neoplasms Stomach cancer 6.5 1.9 31.6 −9.7 12.2 42.5 6.9
Neoplasms Lip and oral cavity cancer 6.2 1.8 4.3 3 21.1 36.4 6.8
Neoplasms Liver cancer 6.6 2.6 23.6 9.8 13.4 56 6.7
Neoplasms Multiple myeloma 5.5 1.1 5.1 3.2 −1.1 13.8 6.4
Neoplasms Kidney cancer 6.4 2.9 29 5.8 2.1 46.2 6.3
Neoplasms Uterine cancer 5.4 0.5 −1.2 8.8 −7.6 5.9 5.2
Neoplasms Non−melanoma skin cancer 5.4 3.8 4.4 −9.1 0.2 4.7 4.6
Neoplasms Malignant skin melanoma 5.9 1.7 4.1 4.8 13 29.5 4.2
Neoplasms Other pharynx cancer 5.5 2 −38.7 4.4 29.3 2.6 3.5
Neoplasms Cervical cancer 5.8 0.2 −4.1 5.9 14.1 21.9 3.2
Neoplasms Thyroid cancer 6.2 0.5 3.8 7.1 20.8 38.4 3
Neoplasms Gallbladder and biliary tract 
cancer
6 3.2 −9.1 16.3 13.3 29.7 3
Neoplasms Mesothelioma 5.6 1.5 −4.2 −3.6 8.2 7.5 2.8
Neoplasms Hodgkin lymphoma 5.1 −0.5 −5.8 0 28.4 27.2 1.5
Neoplasms Larynx cancer 5.5 2.6 −18.3 13.2 12.2 15.2 1.5
Factors related to the change in Swiss inpatient costs by disease: a 6-factor decomposition 
1 3
Table 8  (continued)














Neoplasms Testicular cancer 6.2 −1.2 4.5 9 24.2 42.6 1.2
Neoplasms Nasopharynx cancer 3 1.3 −12.2 1.5 −14.1 −20.5 0.4
OtherNCD Endocrine, metabolic, blood, 
and immune disorders
5.5 0.4 15.5 1.1 −12.2 10.29 64.8
OtherNCD Urinary diseases and male 
infertility
6.3 2.2 26.8 1.2 6.6 43.1 59.4
OtherNCD Congenital birth defects 5.5 0.7 −6.5 5.8 3.8 9.3 52.5
OtherNCD Gynecological diseases 5.3 −1 −6.9 −0.4 3.7 0.6 43.8
OtherNCD Oral disorders 6.5 −1.6 36.7 2.9 6.8 51.3 7.9
OtherNCD Hemoglobinopathies and 
hemolytic anemias
5.5 1.1 2 3.2 −9.2 2.6 4.9
Digestive Other digestive diseases 5.3 1.3 −5.2 −0.4 −0.5 0.5 61.4
Digestive Inguinal, femoral, and 
abdominal hernia
5.6 1.4 6.2 0 0.1 13.2 34
Digestive Gallbladder and biliary 
diseases
5.4 1.5 1.5 −1.7 −1.4 5.4 33.7
Digestive Appendicitis 5.4 −0.4 −1.5 −1.1 4.6 7 18.8
Digestive Cirrhosis and other chronic 
liver diseases
5.2 0.6 −12.2 4.7 −2 −3.7 18.8
Digestive Paralytic ileus and intestinal 
obstruction
4.9 2.1 −15 1.8 −4.9 −11.1 17.5
Digestive Upper digestive system 
diseases
5.5 1.6 −1.7 1 2.3 8.8 14.9
Digestive Pancreatitis 5.9 0.8 17.9 −1 4.3 27.9 9.9
Digestive Inflammatory bowel disease 5.5 0.2 −10.6 5.2 10.7 11.1 7.9
Digestive Vascular intestinal disorders 6.3 2.2 48 0.6 −19.5 37.6 4.1
Chronic respiratory Other chronic respiratory 
diseases
5.6 −0.1 12.2 −0.4 −4.9 12.4 35.7
Chronic respiratory Chronic obstructive pulmo-
nary disease
5.4 2.4 −3.8 4.6 −1.7 6.9 19.7
Chronic respiratory Interstitial lung disease and 
pulmonary sarcoidosis
5.8 2.6 20.9 10.8 −13.3 26.7 3.9
Chronic respiratory Asthma 5.8 1.1 −16.1 6.2 24.2 21.2 1.3
Chronic respiratory Pneumoconiosis 2.3 1.1 −9.2 −9.2 −9.2 −24 0.1
Neurological Epilepsy 5.5 0 3.7 2.1 −2.4 8.87 21.5
Neurological Other neurological disorders 5.9 1.1 −1.3 1.4 17.8 24.9 21.4
Neurological Alzheimer’s disease and 
other dementias
5.3 3.3 4.1 1.8 −13.1 1.3 6.5
Neurological Parkinson’s disease 5.2 2.7 −13.3 3.2 4.44 2.3 5.6
Neurological Multiple sclerosis 4.5 0.7 −12.1 −7.2 −4.5 −18.6 1
Neurological Motor neuron disease 4.7 2.6 −26.2 3.3 −1.4 −17.1 0.9
Neurological Headache disorders 6.6 −0.4 35.7 4.6 13.6 60 0.8
Skin and subcutaneous Skin and subcutaneous 
diseases
5.3 1.4 2.7 −0.9 −7.1 1.4 36.6
Sense organ Blindness and vision impair-
ment
5.4 2 −14.7 2.8 7.6 3.1 18.2
Sense organ Other sense organ diseases 5.1 1.3 −8.3 −1.9 −2.8 −6.7 9.8
Diabetes Chronic kidney disease 5 1 −18.3 1.4 2.8 −8.2 12.8
Diabetes Diabetes mellitus 6.4 2.3 17.3 6.3 16.6 48.9 11.4
Diabetes Acute glomerulonephritis 4.9 2.2 58.3 58.3 58.3 182 0.1
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substance use Drug use disorders 4.8 −1.1 22.8 −2.1 −44 −19.6 3
Mental Mental disorders 5.8 2.1 0.6 2.2 11.6 22.3 27.6
Communicable Maternal and neonatal 
disorders
5.8 0.3 13 1.7 −1.2 19.5 104.6
Communicable Other infectious diseases 5.5 2 −32 −0.6 31.6 6.4 89.8
Communicable Respiratory infections and 
tuberculosis
6 2.7 24.9 0.2 −6 27.8 52.1
Communicable Enteric infections 5.5 2 0.5 −0.9 4.6 11.7 11.7
Communicable Nutritional deficiencies 5.3 2.2 −6.8 −1.4 4.9 4.3 3.8
Communicable HIV/AIDS and sexually 
transmitted infections
4.9 −0.9 −10.9 0.4 0.9 −5.5 2.9
Communicable Neglected tropical diseases 
and malaria
5.9 −1.3 −11.4 6.1 27 26.4 0.9
Injuries Injury of one body part 5.6 1.5 −3.6 0.9 9 13.4 257.7
Injuries Injury of multiple body parts 6.3 1.5 28.8 1.5 3.7 41.8 88.4
Injuries Unintentional injuries 4.8 0.9 −15.2 0.7 −9.7 −18.6 12.5
Well care Well care 5.4 −0.1 −3.2 −0.4 3.3 5 115.7
Non-distinctive Non-distinctive codes 5 2 −9.8 0.2 −8.5 −11.2 46.1
Fig. 9  Contribution of distribu-
tional sections to total change in 
costs by disease, GBD level2
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